Back to search
FDAFDA · Food and drugs·Recall number D-0536-2021

Rybelsus (semaglutide) Tablets 7 mg Once daily Each tablet contains 7 mg semaglutide 30 tablets 3 blister packs. Each pack contains 10 tablets. Rx only NDC 0169-4307-13 Manufactured by: Novo Nordisk A/S DK-2880 Bagsvaerd, Denmark

Published June 2, 2021 · Recall initiated: March 15, 2021

Summary

FDA records drug Class II recall D-0536-2021, published June 2, 2021 and initiated March 15, 2021. Recalling firm: Cardinal Health Inc.; Status: Terminated; Reported quantity: 1189 cartons; Lot: K082347. Class II means possible temporary or medically reversible effects, or a remote probability of serious health consequences.

Status when published: Terminated — openFDA updates weekly, so this field may not reflect the current status. Always confirm with the official notice.

What's the hazard

CGMP Deviations: Intermittent exposure to temperature excursion during storage.

What to do

Voluntary: Firm initiated · Letter

Get an email when a new FDA recall like this is published

Free. We only write when there's a new recall that matches. Unsubscribe in one click.

Recall details

Manufacturer
Cardinal Health Inc.
Distributor
FL, GA, SC
Lot
K082347
Risk classification
Class II
Area (FDA)
drug
Country
United States

Related recalls

Questions about this recall

Was Rybelsus (semaglutide) Tablets 7 mg Once daily Each tablet contains 7 mg semaglutide 30 tablets 3 blister packs. Each pack contains 10 tablets. Rx only NDC 0169-4307-13 Manufactured by: Novo Nordisk A/S DK-2880 Bagsvaerd, Denmark recalled?

Yes. FDA published recall D-0536-2021 on June 2, 2021. Reported hazard: CGMP Deviations: Intermittent exposure to temperature excursion during storage.

What should I do if I have this product?

Voluntary: Firm initiated · Letter